Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WIL Research Laboratories, a contract research organization, and WIL Research Holding Company, have acquired Midwest BioResearch, a provider of drug disposition and toxicology services.
Subscribe to our email newsletter
Midwest BioResearch’s significant expertise in immunoanalytical and bioassay techniques and small molecule bioanalysis, supporting both clinical and nonclinical research, and its expertise in genetic toxicology, is expected to complement WIL Research’s contract research service offerings that include expertise in chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry and metabolism.
Michael Schlosser, president and founder of Midwest BioResearch, will continue to lead the existing Skokie, Illinois site reporting to Christopher Chengelis, vice president and chief scientific officer at WIL Research.
Dr Chengelis said: “Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities. We also benefit from a world-class staff with significant pharmaceutical and biotechnology industry experience and the addition of a program services consulting group.”